Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
89
resultados
Última actualización
11/09/2026 [07:26:00]
Resumen de: US20260263534A1
The present disclosure provides a method of treating a solid tumor cancer. The method includes administering a combination to a subject in need thereof. The combination includes at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The present disclosure also provides an anti-tumor agent for use in a method of treating cancer. In such instances, the anti-tumor agent may include the combination.
Resumen de: CN122705692A
本发明提供了一种能响应温度变化从而诱导下游基因表达的重组盐单胞菌及其构建方法和应用。所述重组盐单胞菌利用突变筛选得到的Toll/白介素‑1受体类似蛋白A(TIR‑like protein A,TlpA)构建的37°C及42°C诱导型启动子，并且对该37°C及42°C诱导型启动子进行了全面表征。所述重组盐单胞菌可以实现在30°C升温至37°C及37°C升温至42°C时启动目的基因表达的目的，且采用这种方法实现基因的诱导表达，具有操作简单、成本低的特点。
Resumen de: US20260256858A1
0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.
Resumen de: WO2026180700A1
The present invention provides a modified quorum sensing circuit, wherein the modified quorum sensing circuit comprises a quorum sensing synthase and a quorum sensing receptor, wherein the quorum sensing synthase and the quorum sensing receptor are transcriptionally separated.
Resumen de: US20260248866A1
0000 An object of the present disclosure is to provide (i) a novel bacteriophage having lytic activity against a Salmonella species such as S. enteritidis or a lytic agent including the same, (ii) a bacteriophage having a broad host range against Salmonella species or a lytic agent including the same, (iii) a host-specific bacteriophage or an effective lytic agent for a Salmonella species including the same, or (iv) a bacteriophage or a lytic agent including the same, capable of effectively controlling S. typhimurium, particularly S. typhimurium having multidrug resistance. The present disclosure provides bacteriophages having specific genomic DNA sequences, lytic agents for Salmonella species including the same, and compositions including the same.
Resumen de: US20260248139A1
A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.
Resumen de: US20260248865A1
0000 A bacteriophage having a wide host range for bacteria of the genus Salmonella is provided. The bacteriophage has bacteriolytic activity against bacteria of the genus Salmonella. The bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence. Methods of using the bacteriophage are also provided.
Resumen de: CN122609470A
本发明属于生物医药领域，具体涉及一种胸苷依赖型的鼠伤寒沙门氏菌工程菌及其组合物与应用。所述工程菌以鼠伤寒沙门氏菌VNP20009为出发菌株，经敲除胸苷酸合成酶基因thyA和插入腺苷脱氨酶编码基因，获得生长依赖外源嘧啶核苷酸、胞内表达或外膜表达腺苷脱氨酶的工程菌；胞内表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑cADD，保藏号为CGMCC No.37959；外膜表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑wADD，保藏号为CGMCC No.37956。该工程菌可肿瘤靶向定植、安全性更高，能在肿瘤局部降解腺苷、解除免疫抑制，联合放疗或免疫检查点抑制剂时可显著抑制实体瘤生长。
Resumen de: US20260242806A1
0000 The invention relates to re-engineering of a natural microbial syringe for loading of effector proteins that are not naturally found as cargo of the specific syringe. The cargo, that is one or more effector protein and proteins required for packing, can be up to 300 kDa and can be proteins such as toxins, therapeutic proteins, and gene modification tools. The re-engineering of the natural syringe result in a contractile injection system that allows packing of large cargo and cargo combinations, such as toxin-chimeras. The system comprises a Conserved Virulence Cassette encoding the syringe structure and is co-expressed with a sequence encoding cargo and a signal peptide. The signal peptide comprises a packing motif that enables packing of cargo into the syringe. The contractile injection system can be used for agricultural purposes as well as for medicinal purposes.
Resumen de: US20260240985A1
0000 The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an auto-transporter comprising transmembrane linker and a trans-porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.
Resumen de: US20260242416A1
Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach leading to identification of numerous antimicrobial peptides from known genomic sequences is described.
Resumen de: AU2026208127A1
Compositions, methods, kits, and uses are provided for detecting the presence of Salmonella, Shigella, Campylobacter, and Shigatoxigenic Escherichia coli (STEC) in samples. In some embodiments, the compositions, methods, kits, and uses comprise one or more oligonucleotides or the use of one or more oligonucleotides. ul u l
Resumen de: US20260243764A1
Described herein is a biosensor for detecting the presence of a target molecule in a sample. The biosensor comprises: a polymeric hydrogel; a colorimetric indicator entrapped in the polymeric hydrogel; and an oligonucleotide that crosslinks the polymeric hydrogel, wherein the oligonucleotide is separated in the presence of the target molecule, thereby releasing the colorimetric indicator from the hydrogel.
Resumen de: WO2025080776A2
Aspects of the invention described herein relate to a vaccine composition comprising at an antigenic polysaccharide and an immunomodulatory amount of a sialic acid binding moiety, wherein the sialic acid binding moiety comprises sialic acid binding domain (SBD) which is not fused to an antigenic polypeptide.
Resumen de: WO2022032100A2
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Cell Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.
Resumen de: CN122582271A
本发明公开一种基于细菌的肿瘤原位疫苗，包括灭活细菌和腺苷脱氨酶，所述灭活细菌为大肠杆菌(Escherichia coli) Nissle 1917或减毒鼠伤寒沙门氏菌(VNP 20009)中的任意一种或两种。本发明的肿瘤原位疫苗对宿主脏器无明显毒副作用，具有良好的安全性，生产制备工艺简单、成本低；可通过瘤内注射方式刺激机体先天性和适应性免疫系统，增强抗肿瘤免疫，抑制肿瘤细胞生长，有效预防肿瘤的发生发展和复发转移。
Resumen de: KR20260124251A
본 발명은 TolC 유전자가 결손된 신규 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) CK139 균주 및 상기 균주가 분비하는 단백질에 관한 것으로, 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) 균주에서 외막 단백질인 TolC에 대한 유전자가 결손된 돌연변이 균주인 살모넬라 엔테리카 타이피뮤리움(Salmonella enterica Typhimurium) CK139 균주가 철 이온의 농도에 따라 분비 단백질의 패턴이 유의적으로 변화되는 것을 확인하고, 낮은 철 이온 농도에서 에코틴(ecotin) 단백질의 분비가 유의적으로 증가되는 것을 확인하였으며, 상기 CK139 균주 또는 에코틴(ecotin) 단백질을 마우스에 주사한 결과 염증성 장질환이 악화됨을 확인함에 따라 상기 CK139 균주 또는 에코틴(ecotin) 단백질을 염증성 장질환의 악화 인자를 확인하고, 이를 이용하여 염증성 장질환 동물 모델의 제조 방법을 제공한다.
Resumen de: CN122563840A
本发明公开了一种肿瘤靶向定植且肠道可条件性清除的工程菌及其应用。该工程菌首次整合了“肿瘤专性定植回路”与“大肠杆菌素条件性敏感回路”：通过营养缺陷型突变（ΔaroA）与缺氧依赖性增殖回路（P hypox ‑ftsZ）的双重锁定，实现严格的肿瘤微环境专性定植；通过外源大肠杆菌素受体基因与时间延迟免疫蛋白回路的协同，实现在肠道穿越窗口期（约0‑4小时）内对大肠杆菌素耐受、穿越完成后恢复敏感的条件性清除能力。本发明工程菌解决了口服活菌制剂“既要高效穿越肠屏障、又要彻底清除肠道残留”的核心矛盾，为肿瘤细菌疗法提供了安全、可控的活体底盘，可广泛用作定植菌或效应菌应用于各类级联放大肿瘤免疫治疗系统。
Resumen de: CN115715198A
The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain, the Salmonella typhi Ty21a strain comprising a DNA molecule, the DNA molecule comprising an eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the invention relates to the application of the DNA vaccine to prevention and/or treatment of the coronavirus disease COVID-19 or SARS-CoV-2 infection.
Resumen de: US20260232581A1
0000 The present disclosure provides pharmaceutical compositions for use in delivering therapeutics, such as vaccines or biologic material, to the nasal cavity or the deep lungs. In particular, the pharmaceutical compositions may preferentially deposit on the lower or middle turbinate region and the nasopharynx region of the nasal cavity. In other aspects the pharmaceutical compositions may be used to generate powders that penetrate the deep lungs. Also, provided herein are methods of preferential delivery to these regions.
Resumen de: WO2026170052A1
The present invention provides for enrichment of animal foodstuffs using endolysin polypeptides or fragments thereof, which possess antimicrobial activity (e.g., against gram-negative bacteria, such as Salmonella enterica). The invention also provides for nucleic acid molecules encoding the endolysin, and methods of their production. Also provided are compositions comprising the endolysins, or comprising any of the means for producing the endolysin (e.g., a host cell, lysate, or dried product, etc.) that has antimicrobial activity, for the use of said compositions in a method of reducing the population of gram-negative bacteria in a foodstuff, or preventing or treating a disease or disorder in an animal.
Resumen de: EP4790026A1
0001 Apparatus for treating various fluids, such as wine, must, water, oil, sauce, fruit juice, and others, to prevent contamination or the development and spread of diseases such as salmonella and legionella. The apparatus allows to avoid excessive proliferation of colonies of bacteria and yeasts which, if present in excessive quantities, can cause mould and pathogens in general. The apparatus comprises a container body containing a reticular cathode and anode that allow the liquid to pass through and are powered by an electrical connector that receives electrical current from a power supply controlled by an electronic control unit. The container body is configured to be immersed in the liquid to be treated, allowing the liquid to flow through the cathode and anode, which generate a pulsed electric field. The electrical signal has a frequency of about 300 Hz, an amplitude of 100V and pulses of few milliseconds. To increase the efficiency of the treatment, the signal changes polarity every 90 seconds.
Resumen de: WO2022036159A2
Provided are attenuated immunostimulatory bacteria with genomes that are modified to, for example, reduce toxicity and improve the anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor- resident myeloid cells, improving resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T-cell function. Also provided are immunostimulatory bacteria for use as vaccines, and for delivery of mRNA. The increase in colonization of phagocytic cells improves the delivery of encoded therapeutic products to the tumor microenvironment and to tumors and permits, among other routes, systemic administration of the immunostimulatory bacteria. The increase in colonization of phagocytic cells also provides for use of immunostimulatory bacteria for direct tissue administration for use as vaccines.
Resumen de: WO2025021695A1
The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.
Nº publicación: CN122521594A 07/08/2026
Solicitante:
爱瑞泰制药公司
Resumen de: US2017000831A1
0001 The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
BOPI
Sede Electrónica
